Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Adhésion au parcours RICA (ERAS) et faisabilité d'une sortie précoce après appendicectomie non compliquée en urgence (APENERAS) (APENERAS)

3 novembre 2026 mis à jour par: Susana Postigo Morales, Hospital Galdakao-Usansolo

APENERAS : Étude observationnelle prospective multicentrique sur l'adhésion au protocole RICA (ERAS), les résultats de sécurité et la faisabilité d'une sortie précoce chez les adultes subissant une appendicectomie non compliquée urgente

This multicenter, prospective observational study (APENERAS) evaluates adherence to the RICA (ERAS Zaragoza 2022) perioperative care pathway in adults undergoing urgent laparoscopic appendectomy for uncomplicated acute appendicitis. The study aims to describe real-world adherence to the pathway across participating hospitals and to explore its association with patient safety and recovery outcomes.

Key outcomes include postoperative complications (including severity), length of hospital stay, and readmissions within 30 days. Patient-reported satisfaction is also assessed using a structured survey. In addition, the study evaluates the feasibility of early discharge/ambulatory management by intention-to-treat, using a standardized checklist of clinical, functional, and social discharge criteria assessed during the first 24 hours after surgery.

No changes to usual clinical care are introduced. Data are collected from routine perioperative management and follow-up.

Aperçu de l'étude

Statut

Complété

Description détaillée

APENERAS is a prospective, multicenter observational study conducted in adult patients undergoing urgent laparoscopic appendectomy for uncomplicated acute appendicitis. The study assesses real-world adherence to the RICA (ERAS Zaragoza 2022) pathway, a structured set of perioperative recommendations intended to optimize recovery and standardize care in urgent surgery settings.

The primary objective is to quantify overall adherence and adherence by individual components of the pathway. Secondary objectives include evaluating the association between adherence and (1) postoperative safety outcomes (complications and severity classification), (2) efficiency outcomes (length of stay), (3) unplanned healthcare use (readmissions within 30 days), and (4) patient experience (satisfaction survey completed at discharge). In addition, feasibility of early discharge/ambulatory management is assessed by intention-to-treat using a standardized discharge-readiness checklist (clinical stability, pain control with oral analgesia, oral tolerance, mobilization, spontaneous urination, wound status, and social support), evaluated during the first postoperative day.

Candidate profiles for early discharge are also explored using established clinical prediction tools (e.g., Saint-Antoine Score), together with demographic and clinical covariates. Follow-up is performed up to 30 days after surgery to capture postoperative events and readmissions.

This study does not involve any experimental intervention, drug, or device, and does not require changes to standard clinical practice. It is based on systematic data collection from routine care processes and clinical records in each participating center.

Type d'étude

Observationnel

Inscription (Réel)

199

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Alicante
      • Elche, Alicante, Espagne, 03203
        • Hospital General Universitario de Elche
    • Barcelona
      • Igualada, Barcelona, Espagne, 08700
        • Hospital Universitari d'Igualada
      • Sabadell, Barcelona, Espagne, 08208
        • Hospital Universitari Parc Taulí
    • Vizcaya
      • Galdakao, Vizcaya, Espagne, 48960
        • Hospital Galdakao-Usansolo

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Adults aged 18-75 years undergoing urgent laparoscopic appendectomy for uncomplicated acute appendicitis in participating hospitals. The study evaluates adherence to the RICA (ERAS Zaragoza 2022) pathway in routine clinical practice, early discharge feasibility (8, 12, and 24 hours after surgery), and safety outcomes (complications, readmissions, reinterventions, and mortality) up to 30 days after surgery. No experimental intervention is introduced.

La description

Inclusion Criteria:

  • Age ≥ 18 and ≤ 75 years.
  • Immunocompetent patients.
  • ASA physical status I-III.
  • Preoperative diagnosis of uncomplicated acute appendicitis (based on clinical assessment, laboratory tests, and imaging such as ultrasound and/or CT according to availability).
  • Indication for urgent appendectomy for uncomplicated appendicitis.
  • Laparoscopic approach.
  • Expected operative time < 90 minutes.
  • Cooperative patient able to understand and follow instructions.
  • Voluntary participation and written informed consent.
  • Adequate social/family support (availability of a responsible adult for transport home and support during the first postoperative days).
  • Travel time from home to hospital < 1 hour and access to transportation.
  • Acceptable home environment for recovery (telephone access and basic habitability/hygiene).

Exclusion Criteria:

  • ASA physical status IV.
  • Age < 18 years or > 75 years.
  • BMI > 35 kg/m² with significant respiratory or cardiovascular complications.
  • Ischemic heart disease class IV or acute myocardial infarction within the last 6 months.
  • Congestive heart failure NYHA class III-IV.
  • Sleep apnea or severe COPD, or need for home oxygen therapy.
  • Poorly controlled diabetes mellitus.
  • Severe psychiatric disorders, drug addiction, or severe alcoholism.
  • History of major anesthesia-related complications or malignant hyperthermia.
  • Epilepsy.
  • Pregnancy.
  • Use of anticoagulants, MAO inhibitors, systemic corticosteroids, or immunosuppressive drugs.
  • Complicated appendicitis (gangrenous or perforated appendicitis, abscess, diffuse peritonitis).
  • Severe sepsis.
  • Primary open appendectomy or conversion to open surgery.
  • Positive SARS-CoV-2 PCR or symptoms compatible with COVID-19.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Urgent Uncomplicated Appendectomy Cohort

Adults undergoing urgent laparoscopic appendectomy for uncomplicated acute appendicitis in participating hospitals. Perioperative management follows routine clinical practice. The adherence to the RICA (ERAS) pathway items is assessed, along with safety outcomes and early discharge feasibility.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Overall adherence to the RICA (ERAS Zaragoza 2022) pathway
Délai: From day of surgery through postoperative day 1 or hospital discharge (whichever occurs first).

Overall adherence will be quantified as the proportion (%) of prespecified RICA (ERAS Zaragoza 2022) items fulfilled per participant and overall, using the study case report form. Adherence will be reported as a global percentage and by individual pathway components.

From day of surgery through postoperative day 1 or hospital discharge (whichever occurs first).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Early discharge feasibility at 8, 12 and 24 hours after surgery
Délai: 8, 12 and 24 hours after surgery.

Feasibility of early discharge will be assessed by intention-to-treat using a standardized discharge-readiness checklist (clinical stability, respiratory stability, orientation, mobility, oral intake, urination, wound status, and social support/logistics). The proportion of patients meeting all criteria at each timepoint (8h, 12h, 24h) will be reported.

8, 12 and 24 hours after surgery.
Postoperative complications and severity (Clavien-Dindo)
Délai: Up to 30 days after surgery.

Postoperative complications will be recorded and graded according to the Clavien-Dindo classification.

Up to 30 days after surgery.
Length of hospital stay
Délai: From surgery to hospital discharge, assessed up to 30 days after surgery.

Length of stay will be measured as time from surgery to hospital discharge (reported in days and/or hours as available).

From surgery to hospital discharge, assessed up to 30 days after surgery.
Readmission within 30 days
Délai: Up to 30 days after surgery.

Unplanned readmissions for any cause will be recorded.

Up to 30 days after surgery.
Patient satisfaction score
Délai: Up to 30 days after surgery.

Patient satisfaction will be assessed using a structured survey delivered at hospital discharge and collected during postoperative follow-up. The overall satisfaction score (0-10 scale) and relevant domains will be analyzed. Higher scores indicate greater patient satisfaction.

Up to 30 days after surgery.
Saint-Antoine Score for early discharge eligibility prediction within 24 hours after surgery
Délai: Baseline (preoperative; assessed immediately before surgery).

The Saint-Antoine Score is a 5-point preoperative clinical score (range: 0 to 5) calculated at baseline (immediately before surgery) as the sum of five low-risk criteria (each criterion = 1 point; total score 0-5). Higher scores indicate a greater likelihood of eligibility for unplanned early discharge within 24 hours (better discharge readiness/lower-risk profile). Lower scores indicate a lower likelihood of early discharge eligibility. Predictive performance will be described (e.g., proportion eligible across score categories and discrimination metrics, as applicable).

Baseline (preoperative; assessed immediately before surgery).
Reintervention within 30 days
Délai: Up to 30 days after surgery.

Any unplanned reintervention after the index appendectomy, including surgical reoperation (e.g., re-laparoscopy/laparotomy) and other invasive procedures (e.g., percutaneous drainage), will be recorded.

Up to 30 days after surgery.
All-cause mortality within 30 days
Délai: Up to 30 days after surgery.

All-cause mortality will be recorded.

Up to 30 days after surgery.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Bakarne Ugarte-Sierra, PhD, Grupo español de rehabilitación multimodal (GERM)
  • Directeur d'études: José Manuel Ramírez-Rodríguez, PhD, Grupo español de rehabilitación multimodal (GERM)

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

7 décembre 2022

Achèvement primaire (Réel)

27 janvier 2025

Achèvement de l'étude (Réel)

26 février 2025

Dates d'inscription aux études

Première soumission

14 janvier 2026

Première soumission répondant aux critères de contrôle qualité

6 février 2026

Première publication (Réel)

10 février 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data (IPD) underlying the results reported in publications will be shared. The shared dataset will contain coded study IDs and will exclude direct identifiers (e.g., name, medical record number, address). Variables will be minimized/modified as needed to reduce re-identification risk in accordance with GDPR and institutional policies.

Délai de partage IPD

Available beginning 12 months after publication of the primary results and for 5 years thereafter.

Critères d'accès au partage IPD

Access will be granted to researchers with a clear research question and an appropriate analysis plan, subject to review and approval by the study team and compliance with GDPR and applicable institutional policies. Data will be provided in de-identified form after completion of a data sharing agreement. Requests should be submitted by email to: estudioapeneras@gmail.com

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner